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Indirect clinical measures assessing anti-malarial drug transmission-blocking activity in falciparum malaria include
measurement of the duration of gametocytaemia, the rate of gametocyte clearance or the area under the
gametocytaemia-time curve (AUC). These may provide useful comparative information, but they underestimate
dose-response relationships for transmission-blocking activity. Following 8-aminoquinoline administration P. falciparum
gametocytes are sterilized within hours, whereas clearance from blood takes days. Gametocytaemia AUC and clearance
times are determined predominantly by the more numerous female gametocytes, which are generally less drug
sensitive than the minority male gametocytes, whereas transmission-blocking activity and thus infectivity is determined
by the more sensitive male forms. In choosing doses of transmission-blocking drugs there is no substitute yet for
mosquito-feeding studies.Background
The objective of anti-malarial drug treatment is to cure
the malaria infection as rapidly, reliably and safely as
possible [1]. In endemic areas there is another important
public health consideration and that is to stop the
treated infection being transmitted to anopheline mos-
quitoes, and thereby to other people. Treating the asex-
ual stage infection effectively prevents generation of
young gametocytes and it also prevents recrudescences
(which are associated with increased gametocyte carriage
rates). This reduces the transmission potential of the
treated infection [2]. Plasmodium falciparum differs
from the other malaria parasites of humans in that the
emergence of gametocytaemia is delayed with respect to* Correspondence: nickw@tropmedres.ac
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unless otherwise stated.asexual parasitaemia. The anti-malarial drugs which are
used to treat falciparum malaria also kill young developing
sexual stage parasites but they have little or no activity
against the mature transmissible gametocytes. Treated in-
fections are an important source of transmission especially
in areas of low, unstable malaria transmission. Artemisinin
combination treatment (ACT), the first-line treatment for
falciparum malaria, reduces gametocyte carriage more than
do other anti-malarial treatments [3-6], but even ACTs do
not eliminate mature transmissible P. falciparum gameto-
cytes [3-9]. Preventing these patients’ infections from trans-
mitting falciparum malaria requires treatment with a
specific gametocytocide, and the only generally available
drug is the 8-aminoquinoline, primaquine [6-8,10]. Prima-
quine rapidly sterilizes the infection, thereby reducing its
transmissibility [10]. Given together with an effective treat-
ment for the asexual stage parasites, only one dose is re-
quired. Historically this dose has been 0.5-0.75 mg base/kg
[11]. Primaquine taken with food is generally well tolerated.
The main adverse effect of the 8-aminoquinolines is dose-This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
ab
Figure 1 Dose–response relationships for single-dose primaquine in
reducing the infectivity of Plasmodium falciparum-infected subjects
to anopheline mosquitoes. Pooled data from all studies conducted [13].
Vertical axes shows the proportions of fed anopheline mosquitoes which
were infected. Upper (a): Oocyst formation assessed from blood sampled
48 hours after primaquine dose; Lower (b): Sporozoite formation assessed
from blood sampled 48 hours after primaquine dose. Primaquine given
with an artemisinin derivative is shown in green circles, and with no
anti-malarial or a non-artemisinin derivative is shown in red circles. In
these studies 29 patients received no primaquine. The size of the circle
is proportional to the number of subjects in each group (shown within).
Corresponding adult primaquine doses are indicated in square boxes.
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phosphate dehydrogenase (G6PD) deficiency [10,11]. G6PD
deficiency is very common in many malaria-endemic
regions. In some areas concerns over safety in patients
with G6PD deficiency have limited deployment of prima-
quine as a gametocytocide [11].
In efforts to contain and eliminate artemisinin-resistant
falciparum malaria it is particularly important that all pos-
sible measures to reduce malaria transmission are taken.
The World Health Organization (WHO) has recently rec-
ommended that the single primaquine dose for use as a P.
falciparum gametocytocide (given together with an ACT)
should be reduced to 0.25 mg base/kg as this lower dose is
safer and, on the basis of the available data from direct
transmission-blocking assessments from mosquito-feeding
studies, was considered to be as effective as higher doses
in reducing transmissibility [12-14] (Figure 1). Others have
provided guidance on primaquine doses based on studies
using only indirect measures reflecting P. falciparum
gametocytaemia clearance [15]. This overview assesses the
therapeutic relevance of the different measures that have
been used as a basis for treatment recommendations for
P. falciparum gametocytocides (notably primaquine).
Dosing recommendations based on gametocytaemia;
the Cochrane Review
A recent systematic review evaluating the role of prima-
quine in reducing P. falciparum transmission has rejected
the WHO conclusions derived from the mosquito feeding
data: “Current policy recommendations that 0.25 mg/kg
PQ should be added as a single dose to primary treatment
for P. falciparum malaria in areas that are targeting elim-
ination or are facing artemisinin resistance are based on
judgments and inferences rather than reliable evidence of
an effect at this dose” [15]. The Cochrane Review con-
cluded that “primaquine does reduce the duration of in-
fectiousness” (which was equated with the period that
gametocytes are detected circulating in the blood) when
given at doses of 0.4 mg/kg or above (high quality evi-
dence) but “for the currently recommended low dose regi-
men, there is little direct evidence to be confident that the
effect of reduction in gametocyte prevalence is preserved”
[15]. This negative conclusion was based on two studies
that evaluated P. falciparum gametocyte clearance follow-
ing primaquine given in doses less than 0.4 mg/kg. The
first study was a comparative assessment of asexual and
sexual parasite clearance times following seven-day regi-
mens of quinine given either alone or together with one of
the following: tetracycline, primaquine 0.25 mg base/kg,
primaquine 0.5 mg/kg, or with artesunate given alone or
together with primaquine 0.5 mg/kg (Figures 2 and 3) [4].
There were no significant differences in gametocyte clear-
ance times (GCTs) between the low dose (0.25 mg/kg/d)
and the high dose (0.5 mg/kg/d) primaquine-quinineregimens. The original paper [4] reported that “combina-
tions containing primaquine resulted in significantly
shorter GCTs” and concluded that “artesunate predomin-
antly inhibits gametocyte development whereas prima-
quine accelerates gametocyte clearance in P. falciparum
malaria” [4].
In contrast, the Cochrane analysis of the published
study concluded that addition of primaquine 0.25 mg/kg
to quinine “did not demonstrate an effect on gametocy-
taemia” [15]. This appears to be a mistake derived both
from a mix-up between the reported effects of the lower
Figure 2 Gametocyte clearance following different drug regimens in falciparum malaria. Times from appearance of gametocytaemia
(= 0 if gametocytaemia present on admission) to disappearance of gametocytaemia after different seven-day drug regimens in adults with acute
falciparum malaria studied in Thailand [4]. Primaquine was given daily in a dose of 0.25 mg base/kg or *0.5 mg/kg.
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ance times were shorter, not longer, with the 0.25 mg/kg
dose compared to the 0.5 mg/kg dose as shown in
Figure 2), and also misreading or misinterpretation of a
table describing proportions of patients who were gameto-
cytaemic. Although the relevance of a seven-day prima-
quine regimen to single-dose gametocytocidal use is
uncertain, the Cochrane analysis used these data to argue
that a primaquine dose of 0.25 mg/kg had no effect on
gametocyte clearance – which is incorrect.
The second study of low dose primaquine assessed in the
Cochrane Review was a detailed recent comparison ofFigure 3 Durations of gametocytaemia following different drug regim
Plasmodium falciparum gametocytaemia following quinine alone compared
These are the same patients as in Figure 2.gametocyte clearance following artemether-lumefantrine
treatment of 468 Ugandan children with falciparum malaria
[16]. The children were randomized to receive placebo or
single primaquine doses of 0.1, 0.4 or 0.75 mg/kg. Gameto-
cyte carriage was measured by a sensitive mRNA PCR
method [16]. The results showed that in terms of gameto-
cyte carriage reduction primaquine 0.4 mg/kg was non-
inferior to 0.75 mg/kg. The gametocyte clearances following
the 0.1 mg/kg dose did cross the non-inferiority margin
(compared with 0.75mg/kg) and occupied an intermediate
position compared with placebo (Figure 4). The Cochrane
analysis concluded that “the trial evaluating low dose PQens in falciparum malaria. The comparison of durations of
with quinine plus 0.25 mg base/kg from Pukrittayakamee et al. [4].
Figure 4 Dose–response relationship for primaquine in reducing the duration of (female) gametocyte carriage assessed by Pfs25
transcripts. Mean (95%CI) duration of female gametocyte carriage in Ugandan children with falciparum malaria treated with artemether-lumefantrine
(AL) and different doses of primaquine as reported by Eziefula et al. [16]. Duration was estimated by fitting of a deterministic compartmental
mathematical model to repeated Pfs25 quantitative real time nucleic acid sequence- based analysis gametocyte prevalence estimates. The vertical
dashed line indicates the set threshold for non- inferiority compared with the primaquine 0.75 mg/kg reference group (non-inferiority margin of
2.5 days). The currently recommended 0.25 mg/kg dose is indicated by the horizontal line.
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interpreting dose-response studies (or indeed any continu-
ous series) all data should be taken into account. By ex-
trapolation from the observed dose-response relationship,
the currently recommended 0.25 mg/kg primaquine dose
would be predicted to reduce the duration of gametocyte
carriage by between 50 and 100% of the maximum observed
(Figure 4). Further studies are underway to assess whether
this prediction is correct. Whilst the published study cannot
be used to predict confidently what effect primaquine
0.25 mg/kg would have had; to use it as evidence of “no
effect” is also incorrect. Aside from these misinterpretations,
it is questionable whether dosage recommendations for
drugs which are given to reduce malaria transmissibility
should be derived primarily from studies reporting indirect
measures based on gametocyte densities, such as the
proportion of patients with gametocytaemia on day 8 or the
area under the gametocyte time curve, as surrogates of
transmission-blocking activity and thus infectivity [15].
Transmission of human malaria requires that the ga-
metocytes are infectious to feeding anopheline mosquito
vectors. Mosquito-feeding studies assess transmission-
blocking effects directly and are therefore the most ap-
propriate way to measure the pharmacodynamic effect
for which the drug is prescribed. However, they are no-
toriously difficult, and as a consequence only few have
been conducted [10]. It is much easier to measure gameto-
cyte densities over time in blood samples either by micros-
copy or by molecular methods, and so there are many
more data on these indirect assessments [2-5,7-9,16,17].
These indirect measures based on gametocyte densities in
blood have been used in drug evaluations based on the as-
sumption that their results agree closely with transmission-
blocking activity and can therefore be substituted for dir-
ect assessments. But it is well known that gametocytaemiadoes not equate with infectivity [10,18]. The generally
sigmoid relationship between gametocyte density and
mosquito infectivity is very variable with some patients
infecting mosquitoes without detectable gametocytaemia
and others with high densities not being infectious.
Gametocyte biology
Transmission of malaria requires that a feeding female
anopheline vector mosquito ingests at least one mature
male and one mature female gametocyte in a blood meal,
and that the subsequent ookinete forms an oocyst in the
mosquito’s gut wall. Once the oocyst has matured it rup-
tures liberating sporozoites which migrate to the salivary
glands. Successful inoculation of the sporozoites transmits
malaria. For some drugs (e.g., antifolates) the transmission-
blocking effects are more evident in the mosquito
(sporontocidal activity) which would not be reflected in
indirect assessments of transmission-blocking activity
from serial gametocyte counts. Malaria gametocytes arise
from blood stage schizonts, which have committed to sex-
ual stage development, so they arise from asexual parasites
[18-20]. In falciparum malaria, in contrast to the other
malaria infections of humans, the emergence of gameto-
cytes is delayed [10,18,20] (Figure 5). Gametocytaemia
peaks seven to ten days after the peak in asexual stage
parasite densities [21]. The younger, more drug sensitive,
sexual stages (Stages I to IV) are sequestered and then
released back into the circulation as Stage V gametocytes.
The ratio of female to male gametocytes is unequal in
falciparum malaria with a strong female bias in most
studies [20,23,24]. This is presumably because each male
gametocyte can generate eight microgametes and can
therefore potentially fertilize eight females. There is vari-
ation in reported female to male ratios in acute malaria
with values of 3-5 to 1 being observed mainly [22,24-30]
Figure 5 Male and female gametocytaemia in falciparum malaria. Artificial infection with Plasmodium falciparum for malariatherapy showing
typical delay between the peaks of asexual and sexual parasitaemia, and the respective densities of male and female gametocytes as reported by
Ciuca et al. [22].
White et al. Malaria Journal 2014, 13:483 Page 5 of 13
http://www.malariajournal.com/content/13/1/483(Figure 5). At lower densities in anaemic children with
chronic infections, the female to male gametocyte ratios
are reportedly lower [31], but at the higher densities in
acute infections in which drug assessments are
performed females consistently comprise >70% of the P.
falciparum gametocytes. The biology of male and female
gametocytes is very different. Since the early days of
malariatherapy it was recognized that successful trans-
mission of malaria to mosquitoes required fully mature
gametocytes, and microgametocytes which readily
exflagellated. Crucially it is these minority male (micro)
gametocytes which are usually more drug sensitive [32].
In 1928 Mollow described greater sensitivity of male
gametocytes to the 8-aminoquinoline plasmochin (plas-
moquine, pamaquine) the predecessor of primaquine
[33]. Shute and Maryon in their extensive experience of
artificial infection (malariatherapy) studies noted the
following for P. falciparum: “in our cases female ga-
metocytes almost invariably make their appearance
several days before males and throughout the period
of their presence the females outnumber the males
from between 5 and 20 to 1 or more, and then when
the gametocytes begin to diminish it is the males
which fall off in numbers, and the females appear to
persist for a longer period in the peripheral blood”
[34]. Thus if a drug killed all the male gametocytes
but none of the females, it would sterilize the infec-
tion but gametocyte density would fall by less than
30%.Counting gametocyte densities
Serial asexual parasite counts in blood are used to assess
therapeutic responses to antimalarial drugs. Asexual
parasite clearance times are dependent on several factors
in addition to the drug treatment including initial para-
site counts, proportion of P. falciparum asexual parasites
which are sequestered, immunity, and the counting
methods used [35]. These factors also affect gametocyte
clearance assessments. However gametocyte densities
are orders of magnitude lower in acute malaria so count-
ing errors are correspondingly greater. Gametocyte dens-
ities are usually quantitated on thick blood films with
males and females counted together. There is input to the
circulation from sequestered immature gametocytes while
dead gametocytes are cleared predominantly by the spleen,
so in drug assessments gametocyte input needs to be
deconvoluted from clearance. Artemisinins, and to a lesser
extent other anti-malarials which act on blood stage para-
sites, mainly reduce the input into the circulation whereas
primaquine (and other 8-aminoquinolines) accelerate
clearance [4]. Live gametocytes may circulate for many
days (mean estimates 4.5 to 6.5 days) [36]. Microscopy
cannot distinguish reliably between younger Stage V ga-
metocytes which have just entered the circulation and are
not yet infectious and older Stage V gametocytes which
are infectious. This explains why gametocytaemic patients
with acute malaria may not infect mosquitoes when first
assessed. Microscopy also cannot distinguish between live
and dead gametocytes. Assessment of the sex ratio by
Figure 6 Proposed relationship between male and female
gametocyte clearance and transmission blocking effects in
falciparum malaria. If male gametocytes are more sensitive to
transmission-blocking drugs than female gametocytes, and female
gametocytes predominate, then gametocyte clearance times are
determined by the female gametocytaemia, and transmission-blocking
effects are determined mainly by male gametocytaemia. In this illustration
of gametocytaemia responses to drug treatment clearance half-lives are
one day for male (blue) and two days for female gametocytes (pink).
The limits of gametocyte detection by microscopy and Pfs25mRNA
(which detects predominantly females) are shown by the dotted lines.
If a density of >1,000/mL was required for mosquito infection, then in this
illustration the maximum duration of possible infectivity is three days
compared to a clearance time measured by Pfs25mRNA of seven days. In
fact, drugs such as primaquine sterilize rapidly (Figure 7) suggesting that
loss of infectivity precedes gametocyte clearance so the post-treatment
duration of infectivity in this illustration is likely to be < one day.
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thick films and after treatment with gametocytocidal drugs.
Measurement of mRNA transcripts by qPCR methods is
more sensitive than microscopy. The most widely used is
the QT-NASBA (quantitative nucleic acid sequence-based
amplification) based on detection of Pfs25 transcripts
[8,16,36-38]. Importantly Pfs25, and its orthologues in
rodent malarias, are expressed much more abundantly in
female gametocytes. Indeed they appear to be female specific
(although whether Pfs 25 is transcribed but not expressed in
male gametocytes still needs to be determined) [32,38,39].
Gametocyte clearance assessment
The limited available evidence suggests that gametocyte
clearance is a first order process. Ideally in drug com-
parisons or dose-response assessments this would be
assessed by a first order rate constant or half-life, as for
asexual parasite clearance [35], but gametocyte counts
have seldom been taken frequently enough for this. In-
stead the number of days of detectable gametocytaemia,
proportions of patients with patent gametocytaemia on
specific days (particularly day 7 or day 8), and the area
under the gametocyte time curve (AUC) have been
reported [3,4,7-9,15-17,27,28,36,40-42]. These individual
values are usually pooled for the whole treated patient
groups to account for the majority of patients who do
not have patent gametocytaemia, in order to provide an
estimate of the overall treated population’s gametocyte
carriage at potentially transmissible densities. There are
several important considerations and limitations to these
measures of gametocytocidal drug effects based on
gametocyte density estimates:
1. Gametocyte clearance time estimates depend on the
detection methods used. Times derived from the
more sensitive QT-NASBA are obviously longer
than those based on microscopy. Times derived
from thick film counts per 1000 white cells will be
longer than those per 200 white cells. Fitting a
mathematical model of gametocyte dynamics to
measurements of sub-microscopic gametocyte
prevalence and density [36] to estimate of time to
gametocyte clearance has also been used as a
measure of drug effect [16]. As for asexual parasite
clearance estimates, the times to clearance of
gametocytaemia are proportional to initial
gametocyte densities and the quality and sensitivity
of microscopy or the assay used. Whatever method
is used the higher the initial density the longer it
takes before densities fall below the level of detection
[35] (Figure 6).
2. Male gametocytes are usually more drug sensitive
than females [32], and it is very likely therefore that
they are cleared more rapidly than femalegametocytes [33,34] (Figure 6). Total gametocyte
counts by microscopy reflect the predominant female
gametocyte population (~70-90% of the total) – and
Pfs25 QT-NASBA provides estimates predominantly
or only for female gametocytes. If the male
gametocytes are more drug sensitive than the females,
and they are cleared more rapidly, then the
gametocytaemia AUC is determined largely,
and the proportions of patients with gametocytaemia
on day 8 and the gametocyte clearance times are
determined solely by the less drug-sensitive females
(see Figure 6).
3. It is not known how rapidly dead gametocytes are
cleared from the blood.
4. The relationship between P. falciparum gametocyte
density in blood and infectivity to mosquitoes is very
variable, and is also time dependent (see below) [10,18].
5. The area under the gametocytaemia time curve (AUC),
whilst providing a model independent measure,
assumes that density and time are equally important
in terms of infectivity to mosquitoes, which clearly they
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gametocyte density of 1,000/uL for three days provides
the same AUC as a density of 100/uL for 30 days.
With logarithmic transformation this becomes 4.5
days. High gametocyte densities in patients presenting
with acute symptomatic falciparum malaria are often
not infectious at all, comprising the first wave of
young Stage V gametocytes, whereas low densities
later on are usually infectious [18,34,43]. In the
example above gametocyte carriage at transmissible
densities for 30 days provides ten times more
opportunity for mosquitoes to bite than carriage for
three days.
6. 8-aminoquinolines sterilize malaria infections within
hours, but gametocyte clearance does not start to
increase for > one day [10] (Figure 7), yet the first
day post-treatment may contribute a significant
proportion of the total AUC.
7. Use of the AUC also assumes a linear relationship
between gametocyte density and infectivity whereas
in reality this relationship is sigmoid [10,18,43,44].
Unusual patients with very high gametocyte
densities contribute disproportionately to the
AUC estimate, although their potential infectivity
is saturated.Cochrane review analysis of gametocytaemia in drug
comparisons; the AUC
The Cochrane review [15] used the following formulas
for the area under the gametocyte –time curve.
AUC (days 1 to 15) = ((8-1)*(G1 + G8)/2) + ((15-8)*
(G15 + G8)/2)/14 for days 1 through 15.Figure 7 The temporal dissociation in falciparum malaria between ch
primaquine administration. Individual data from studies of mosquito infe
plasmoquine or primaquine in which oocyst assessments were made in m
were assessed typically in 10-20 mosquitoes 6-7 days after feeding. Each paAUC (days 1 to 29) = ((8-1)*(G1 + G8)/2) + ((15-8)*
(G15 + G8)/2) + ((29-15)*(G29 + G15)/2)/28 for days 1
through 29.
AUC (days 1 to 43) = ((8-1)*(G1 + G8)/2) + ((15-8)*
(G15 + G8)/2) + ((29-15)*(G29 + G15)/2) + ((43-29)*
(G43 + G29)/2)/42 for days 1 through 43
where Gx = mean gametocyte density on day X
(estimated using data from all participants still enrolled
on day X). The log(10) AUC values were estimated using
geometric mean gametocyte density.Infectivity
Assessment of the reduction in infectivity of gameto-
cytes to female anopheline mosquitoes by direct or
membrane feeding measures the pharmacological effect
that is intended [45-49]. Direct feeding is more clinically
relevant, but may be deemed unacceptable by ethics
review boards. Although there may be absolute differ-
ences between the two methods, relative differences
such as the relationships between dose, drug exposure
and transmission-blocking effects should be similar.
Batches of the fed mosquitoes are examined for gut oo-
cysts and later for salivary gland sporozoites to capture
any additional pharmacological effects on parasite devel-
opment in the mosquito. Mosquito-feeding studies are
difficult, laborious and expensive – and therefore seldom
done. Such studies may underestimate transmission-
blocking effects at lower gametocyte densities (which are
more common because of the geometric distribution of
gametocytes in human populations) [10]. In the reported
artificial malaria infection experiments the subjects
commonly had high gametocyte densities for several days,anges in gametocytaemia and effects on infectivity following
ctivity following anti-malarial treatments of falciparum malaria with
osquitoes which fed ~24 hours after drug administration [10]. Oocysts
ir of circles or diamonds represents a studied patient.
Figure 8 The effects of primaquine alone on asexual and sexual parasitaemia in falciparum malaria. Volunteer study reported by Rieckmann
et al. [52] in which primaquine (45 mg base) only was given. The volunteers were infected with the Malayan Camp strain of P. falciparum. Anopheles
stephensi was used as the vector. Volunteer 3 data are shown. Gametocytaemia was quantitated by microscopy, oocysts and sporozoites were assessed
by microscopy after dissection (arrows are the days when mosquitoes were dissected, the numerator is the number positive, the denominator is the
number of mosquitoes dissected). The subsequent infectivity of these mosquitoes (i.e., from the same batches) to other volunteers was also assessed;
a different, healthy, non-immune volunteer was bitten by 75 mosquitoes before, and 12, 24 and 48 hours after primaquine had been given to volunteer 3;
+ (red) denotes that the volunteer became infected with falciparum malaria, 0 denotes the volunteer did not become infected.
Figure 9 Effects of very low dose primaquine on transmissibility of falciparum malaria. Malariatherapy with Plasmodium falciparum
(Panama strain) in two patients who were treated with primaquine 3 mg daily (starting at vertical yellow arrow) as reported by Young et al [53].
Daily direct mosquito feeding was performed. Black line is asexual parasitaemia, vertical lines are temperature (fever), vertical boxes represent
mosquito feeds and dark hatching shows proportion infected. Mosquitoes (10 each) were dissected for oocysts and sporozoites; red + = infected
(≥8 of 10), grey 0 = none infected. Note that infectivity persisted until the fourth day of treatment in patient 1316 (upper panel), and the second
day in patient 1321 (lower panel) and also that the young circulating gametocytes in patient 1316 were initially not infectious. There was a
moderate and delayed effect on gametocytaemia (red dashed line).
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gametocyte densities encountered in natural infections,
and they were highly infectious (Figures 5, 8 and 9). This
resulted in heavy and potentially detrimental mosquito
infections (often >30 oocysts per gut). Drug effects on
gametocyte viability are continuous, but the final effect on
transmission to a mosquito is approximately binary – it is
either infected or not, and only one successful oocyst is all
that is necessary for its potential infectivity. For example,
aside from any sterilizing activity, if there were 1,000 vi-
able gametocytes/uL of blood, a 99% reduction would still
leave 10 gametocytes/uL - which may still be infectious;
whereas if there were 10 gametocytes/uL initially, then a
99% reduction leaves 0.1/uL, which is unlikely to infect
[10]. This contrasts with natural conditions where gam-
etocyte densities in blood are generally much lower than
in the volunteer studies. Indeed the majority of densities
are below the limits of microscopy detection [44,50]. In-
fected wild anopheline mosquito vectors when examined
have correspondingly less intense infections (median 2
oocysts per gut) [51]. Thus artificial infection studies tend
to underestimate transmission-blocking drug effects at a
population level.
Comparison of changes in gametocytaemia and infectivity
reveals important differences. Whereas 8-aminoquinolines
sterilize falciparum malaria infections rapidly, usually
within hours of exposure, gametocyte densities in blood
do not decline for at least one day [10]. This suggests that
at least the first day’s AUC should be discarded from AUC
comparisons involving 8-aminoquinolines. There are
several possible explanations for the significant differences
between gametocytaemia clearance and reduction in
infectivity:Primaq
0.01
Infectiousness
(Males)
100%
50%
0%
Figure 10 Proposed approximate dose-response relationships for prima
in falciparum malaria for primaquine inhibition of infectiousness (blue dashed
and effects on gametocyte clearance (pink dashed curve) reflecting susceptib
transmission-blocking primaquine dose of 0.25 mg/kg. Studies are in progress1. Gametocyte sterilization is rapid but killing is
slower.
2. Clearance of dead gametocytes from the blood is slow.
3. 8-aminoquinolines affect predominantly the
minority male gametocyte population [32].
Clearly if drug effects are directed predominantly
against a minority male gametocyte population [32] then
dose-response assessments based on microscopy, which
does not distinguish between the gametocyte sexes, or
mRNA transcripts produced predominantly or exclu-
sively by female gametocytes, will substantially under-
estimate transmission-blocking activity. The shape of the
derived dose-response relationship may be correct but
use of indirect measures will shift curves to the right, ef-
fectively underestimating transmission-blocking activity
(Figure 10). The dose-response relationship derived from
counts in infections where females predominate, or from
Pfs25 transcripts, is mainly that of female gametocyte
susceptibility, whereas the dose-response relationship
derived from infectivity to mosquitoes is that of the
more sensitive sexual stage, i.e., the male gametocytes.
The primaquine dose-response relationships (given to-
gether with artemether-lumefantrine) derived from fe-
male gametocyte clearance (assessed by Pfs25 mRNA)
suggest that maximum effects on gametocytaemia oc-
curred at doses down to 0.4 mg/kg, with approximately
half maximum effects at 0.1 mg/kg [15] (Figure 4). Dir-
ect estimates of infectivity inhibition from heterogeneous
pooled data obtained from mosquito-feeding studies
suggests maximum effects down to 0.13 mg/kg (Figures 1
and 10) [12]. More data will be needed to refine both
these estimates, and to characterize male and femaleuine dose (mg/kg)
10.1
Gametocyte clearance
(Females)
quine in falciparum malaria. Approximate dose-response relationships
curve) presumably reflecting susceptibility of male gametocytes,
ility of female gametocytes. Arrow shows currently recommended
to characterize these relationships more accurately.
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parison does suggest significant underestimation of the
primaquine transmission blocking dose response relation-
ship by indirect measures based upon gametocytaemia.
Although sub-microscopic densities of gametocytes are
an important source of malaria transmission [7,44,50], this
is usually from asymptomatic individuals at quasi-steady
state parasitaemias. In symptomatic patients it seems rea-
sonable to predict that soon after gametocyte densities fall
below the level of microscopy detection the treated patient
becomes non-infectious – provided that the asexual infec-
tion is cured (i.e., that there is not continued low-level
asexual stage multiplication generating new gametocytes),
and there is no re-infection. If one drug clears gametocy-
taemia more rapidly than another, then it seems reason-
able to conclude that it will also reduce transmissibility
more. More information is needed on these points. How-
ever for the reasons given above determining the dose-
response relationship for a drug (such as primaquine)
based on indirect measures is likely to provide a signifi-
cant underestimate of the relationship for transmission-
blocking activity.
8-aminoquinoline effects on infectivity to mosquitoes
In 1927, shortly after its development, the 8-aminoquinoline
plasmoquine (the predecessor of primaquine) was shown
to clear gametocytaemia more rapidly than asexual stages
in falciparum malaria [54]. By 1929, studies conducted in
Panama showed that plasmoquine rapidly reduced the
infectivity of P. falciparum to anopheline mosquitoes
[55,56]. The transmission-blocking effect (assessed by re-
duction in mosquito oocyst counts) preceded the effects
on gametocytaemia. In subsequent mosquito-feeding stud-
ies plasmoquine doses as low as 10 mg provided rapid and
potent transmission-blocking activity [53,57-60]. Prima-
quine replaced plasmoquine 65 years ago because it was
safer and more potent; it was three times more active
against pre-erythrocytic stages, four to six times better in
radical curative activity against vivax malaria, and was half
as toxic. The transmission-blocking activities of the two
drugs were never compared but, given their structural and
pharmacological similarity, it seems very likely that the
pharmacodynamic effects would also be similar and very
unlikely primaquine would be less active than plasmo-
quine. In 1959, Young reported the effects of an adult
primaquine dose of 3 mg per day (0.05 mg/kg) in two
malariatherapy patients. This very small dose abolished P.
falciparum infectivity to mosquitoes by the third and fifth
days of treatment, which was before any decline in game-
tocytaemia [53] (Figure 9). A recent review found data
from 158 individual gametocytaemic subjects from differ-
ent studies in which infectivity in mosquito-feeding
studies was assessed both by oocyst and sporozoite pro-
duction 24 and 48 hours after drug exposures [13]. Ofthese, 31 subjects received plasmoquine (before 1950) and
127 received primaquine (69 together with an artemisinin
derivative). These studies show clearly that both plasmo-
quine and primaquine rapidly and potently reduce the
infectivity of P. falciparum within hours (Figure 1),
whereas there is a lag phase >24 hours before gametocyte
clearance starts (Figure 7) [10].
Discussion
Assessment of anti-malarial drug transmission-blocking
activity in vivo is problematic. Mosquito-feeding studies
assess directly the effect for which the drug is prescribed
(i.e., to block transmission of malaria) but they are diffi-
cult and laborious, and there are few data as a conse-
quence. Fortunately there is renewed interest in these
assessments and more information to guide evaluations
of transmission-blocking effects drugs and vaccines will
soon become available. Meanwhile indirect measures
based on quantitation of gametocytaemia provide a
guide to the comparative activity of different drugs or
different drug dosages - but they make a number of as-
sumptions. Critically current gametocyte clearance mea-
sures probably underestimate significantly the inhibitory
effects of 8-aminoquinolines on infectivity. This compro-
mises dose-response assessments both for the time of
onset and the magnitude of transmission-blocking activ-
ity. The unique studies of Rieckmann et al. in which vol-
unteers were infected with P. falciparum and managed
to a steady state of parasitaemia highlights the discrep-
ancies between total gametocytaemia, mosquito oocyst
development, sporozoite formation, and the infectivity of
these mosquitoes to naïve volunteers [52,61] (Figure 8).
Early observations on the greater sensitivity of male ga-
metocytes to plasmoquine (pamaquine) [33], the more
rapid clearance of male gametocytes [34], and the recent
study showing large differences between the drug sus-
ceptibility of male and female gametocytes [32] provide
further reason to be cautious in interpreting drug com-
parisons based on total gametocytaemia quantitated by
microscopy or predominantly female gametocytaemia
assessed by quantitation of Pfs25 transcripts. The degree
of underestimation by indirect assessments is unclear as
there have been few simultaneous comparisons. A com-
parison of different studies (albeit with different patient
groups, designs, drug dosages, etc.) in P. falciparum in-
fections (summarized in Figures 1 and 7) suggests a sig-
nificant difference. If infectivity is determined by the
susceptibility of male gametocytes, then this comparison
would suggest that male gametocytes may be more than
three times more susceptible to primaquine than females
(Figures 6 and 10) but further studies are required to
determine whether these predictions are correct. On the
other hand, it seems very unlikely that these indirect
assessments based on gametocyte clearance overestimate
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limit for a dose-response relationship which may be
useful.
More direct assessments of drug effects on male and
female gametocytes individually such as the P. falciparum
dual gamete formation assay (PfDGFA) are an advance
[62,63], and histochemical methods may distinguish live
from dead gametocytes, but for the present for dose-
response assessments there is no substitute for
mosquito-feeding studies (although close attention
must be given to the specific design of these assays
to ensure that the outcomes can be interpreted and
compared usefully) [45-49]. Primaquine is the only
generally available drug, which rapidly and reliably
reduces the transmissibility of P. falciparum malaria
infections from patients presenting with patent gameto-
cytaemia. Unfortunately the 8-aminoquinolines require
hepatic bioactivation which compromises ex vivo assess-
ments. Characterizing sex-specific markers and assessing
the pharmacokinetic-pharmacodynamic relationship for
primaquine’s gametocytocidal activity on male and female
gametocytes in vivo is a research priority. Ideally dose-
response assessments should be performed by comparing
the infectiousness of gametocytaemic blood to anophel-
ine mosquitoes before and after different doses, prefera-
bly with assessment of both oocyst and sporozoite
formation, plasma primaquine concentration measure-
ment (and CYP2D6 genotyping) [64]. Given the pharma-
cokinetic properties and the documented rapidity of
onset (particularly for inhibition of sporozoite formation)
testing before and eight to 24 hours after dosing would
reduce variability in the feeding mosquitoes.
Conclusion
Despite their difficulty, mosquito-feeding studies still re-
main the ‘gold standard’ for the assessment of transmission-
blocking dose-response relationships. More information is
needed on the relative susceptibility of male and female
gametocytes and the kinetics of male and female gameto-
cyte killing, together with direct comparisons with infect-
ivity assessments, before indirect measures can be used
confidently to make dosage recommendations.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
NW conceived of the review and wrote the first draft. All other authors
advised and read and approved the final manuscript.
Acknowledgements
In appreciation of Bob Sinden and his extensive contribution to our
understanding of malaria transmission. NJW, EAA, JR, FMS, MI, KC, SP, CC, GB,
CA, CJW, WRJT, LvS, AMD, NPJD, and FHN are supported by the Wellcome
Trust (Programme Grant 089179) and were part of the Wellcome Trust
Mahidol University Oxford Tropical Medicine Research Programme funded by
the Wellcome Trust. MJD, CD, TB, RG and IC are supported by the Bill and
Melinda Gates Foundation (MD: OPP1043501, CD: OPP1034789, TB:OPP1024438 and OPP1034789, RG and IC A115501); AR is supported by the
Medicines for Malaria Venture (MMV 08/2800). The Wellcome Trust also
supports ACE (090558), CD (091924) and RNP (091625). MJD, KS and PG are
supported by the WorldWide Antimalarial Resistance Network.
Author details
1Mahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical
Medicine, Mahidol University, Bangkok, Thailand. 2Centre for Tropical
Medicine and Global Health, Nuffield Department of Medicine, University of
Oxford, Oxford, UK. 3Department of Life Sciences, Imperial College, London,
UK. 4Myanmar Oxford Clinical Research Unit, Yangon, Myanmar. 5London
School of Hygiene and Tropical Medicine, London, UK. 6Department of
Molecular Tropical Medicine and Genetics, Faculty of Tropical Medicine,
Mahidol University, Bangkok, Thailand. 7Department of Clinical Tropical
Medicine, Faculty of Tropical Medicine, Mahidol University, Bangkok,
Thailand. 8Mahidol Vivax Research Unit, Faculty of Tropical Medicine, Mahidol
University, Bangkok, Thailand. 9Shoklo Malaria Research Unit, Faculty of
Tropical Medicine, Mahidol University, Mae Sot, Tak, Thailand. 10Oxford
University Clinical Research Unit, Hospital for Tropical Diseases, Ho Chi Minh
City, Vietnam. 11Lao-Oxford-Mahosot Hospital-Wellcome Trust Research Unit,
Microbiology Laboratory, Mahosot Hospital, Vientiane, Lao PDR. 12Global and
Tropical Health Division, Menzies School of Health Research and Charles
Darwin University, Darwin, NT, Australia. 13Division of Clinical Pharmacology,
Department of Medicine, University of Cape Town, Cape Town, South Africa.
14Malaria Research and Training Centre, Department of Epidemiology of
Parasitic Diseases, Faculty of Medicine and Odonto-Stomatogy, University of
Sciences, Techniques and Technologies of Bamako, Bamako, Mali. 15Liverpool
School of Tropical Medicine, Liverpool, UK. 16Global Health Group, UCSF
Global Health Sciences, San Francisco, CA, USA. 17World Wide Antimalarial
Resistance Network, Churchill Hospital, Headington, Oxford, UK.
Received: 8 November 2014 Accepted: 29 November 2014
Published: 9 December 2014References
1. WHO: Guidelines for the Treatment of Malaria. 2nd edition. Geneva: World
Health Organization; 2010.
2. Price R, Nosten F, Simpson JA, Luxemburger C, Phaipun L, ter Kuile F, van
Vugt M, Chongsuphajaisiddhi T, White NJ: Risk factors for gametocyte
carriage in uncomplicated falciparum malaria. Am J Trop Med Hyg 1999,
60:1019–1023.
3. Price RN, Nosten F, Luxemburger C, ter Kuile FO, Paiphun L,
Chongsuphajaisiddhi T, White NJ: Effects of artemisinin derivatives on
malaria transmissibility. Lancet 1996, 347:1654–1658.
4. Pukrittayakamee S, Chotivanich K, Chantra A, Clemens R, Looareesuwan S,
White NJ: Activities of artesunate and primaquine against asexual- and
sexual-stage parasites in falciparum malaria. Antimicrob Agents Chemother
2004, 48:1329–1334.
5. Drakeley CJ, Jawara M, Targett GA, Walraven G, Obisike U, Coleman R,
Pinder M, Sutherland CJ: Addition of artesunate to chloroquine for
treatment of Plasmodium falciparum malaria in Gambian children causes
a significant but short-lived reduction in infectiousness for mosquitoes.
Trop Med Int Health 2004, 9:53–61.
6. Chotivanich K, Sattabongkot J, Udomsangpetch R, Looareesuwan S, Day NP,
Coleman RE, White NJ: Transmission-blocking activities of quinine,
primaquine, and artesunate. Antimicrob Agents Chemother 2006,
50:1927–1930.
7. El-Sayed B, El-Zaki SE, Babiker H, Gadalla N, Ageep T, Mansour F, Baraka O,
Milligan P, Babiker A: A randomized open-label trial of artesunate-
sulfadoxine-pyrimethamine with or without primaquine for elimination
of sub-microscopic P. falciparum parasitaemia and gametocyte carriage
in eastern Sudan. PLoS One 2007, 2:e1311.
8. Shekalaghe S, Drakeley C, Gosling R, Ndaro A, van Meegeren M, Enevold A,
Alifrangis M, Mosha F, Sauerwein R, Bousema T: Primaquine clears
submicroscopic Plasmodium falciparum gametocytes that persist after
treatment with sulphadoxine-pyrimethamine and artesunate. PLoS One
2007, 2:e1023.
9. Okell LC, Drakeley CJ, Ghani AC, Bousema T, Sutherland CJ: Reduction of
transmission from malaria patients by artemisinin combination
therapies: a pooled analysis of six randomized trials. Malar J 2008, 7:125.
White et al. Malaria Journal 2014, 13:483 Page 12 of 13
http://www.malariajournal.com/content/13/1/48310. White NJ: Primaquine to prevent transmission of falciparum malaria.
Lancet Infect Dis 2013, 13:175–181.
11. Ashley EA, Recht J, White NJ: Primaquine: the risks and the benefits. Malar
J 2014, 13:418.
12. WHO: Single Dose Primaquine as a Gametocytocide in Plasmodium
Falciparum Malaria; Updated WHO Policy Recommendation. Geneva: World
Health Organization; 2012 [http://www.who.int/malaria/publications/atoz/
who_pq_policy_recommendation/en/]
13. White NJ, Qiao LG, Qi G, Luzzatto L: Rationale for recommending a lower
dose of primaquine as a Plasmodium falciparum gametocytocide in
populations where G6PD deficiency is common. Malar J 2012, 11:418.
14. Recht J, Ashley EA, White NJ: Safety of 8-aminoquinoline Antimalarial Medicines.
Geneva: World Health Organization; 2014.
15. Graves PM, Gelband H, Garner P: Primaquine or other 8-aminoquinoline
for reducing P. falciparum transmission. Cochrane Database Syst Rev 2014,
6:CD008152.
16. Eziefula AC, Bousema T, Yeung S, Kamya M, Owaraganise A, Gabagaya G,
Bradley J, Grignard L, Lanke KH, Wanzira H, Mpimbaza A, Nsobya S, White
NJ, Webb EL, Staedke SG, Drakeley C: Single dose primaquine for
clearance of Plasmodium falciparum gametocytes in children with
uncomplicated malaria in Uganda: a randomised, controlled, double-
blind, dose-ranging trial. Lancet Infect Dis 2014, 14:130–139.
17. Smithuis F, Kyaw MK, Phe O, Win T, Aung PP, Oo AP, Naing AL, Nyo MY,
Myint NZ, Imwong M, Ashley E, Lee SJ, White NJ: Effectiveness of five
artemisinin combination regimens with or without primaquine in
uncomplicated falciparum malaria: an open-label randomised trial.
Lancet Infect Dis 2010, 10:673–681.
18. Bousema T, Drakeley C: Epidemiology and infectivity of Plasmodium
falciparum and Plasmodium vivax gametocytes in relation to malaria
control and elimination. Clin Microbiol Rev 2011, 24:377–410.
19. Smalley ME: Plasmodium falciparum gametocytes: the effect of
chloroquine on their development. Trans R Soc Trop Med Hyg 1977,
71:526–529.
20. Sinden RE: Sexual development of malarial parasites. Adv Parasitol 1983,
22:153–216.
21. Thomson D: A research into the production, life and death of crescents
in malignant tertian malaria, in treated and untreated cases, by an
enumerative method. Ann Trop Med Parasitol 1911, 5:57–85.
22. Ciuca M, Ballif L, Chearescu M, Lavrinenko N: Contribution à l’étude de
l’infection expérimentale au Plasmodium falciparum. Hamburg: Festchrift
Institute Bernard Nocht; 1937:81–101.
23. Mair GR, Braks JAM, Garver LS, Wiegant JCAG, Hall N, Dirks RW, Khan SM,
Dimopoulos G, Janse CJ, Waters AP: Regulation of sexual development of
Plasmodium by translational repression. Science 2006, 313:667–669.
24. Robert V, Sokhna CS, Rogier C, Ariey F, Trape JF: Sex ratio of Plasmodium
falciparum gametocytes in inhabitants of Dielmo, Senegal. Parasitology
2003, 127:1–8.
25. Talman AM, Domarle O, McKenzie FE, Ariey F, Robert V:
Gametocytogenesis: the puberty of Plasmodium falciparum. Malar J 2004,
3:24.
26. Sowunmi A, Balogun ST, Gbotosho GO, Happi CT: Plasmodium falciparum
gametocyte sex ratios in children with acute, symptomatic,
uncomplicated infections treated with amodiaquine. Malar J 2008, 7:169.
27. Sowunmi A, Balogun ST, Gbotosho GO, Happi CT: Plasmodium falciparum
gametocyte sex ratios in symptomatic children treated with antimalarial
drugs. Acta Trop 2009, 109:108–117.
28. Kar PK, Dua YK, Gupta NC, Gupta A, Dash AP: Plasmodium falciparum
gametocytaemia with chloroquine chemotherapy in persistent malaria
in an endemic area of India. Indian J Med Res 2009, 129:299–304.
29. Sowunmi A, Gbotosho GO, Happi CT, Folarin OA, Balogun ST: Population
structure of Plasmodium falciparum gametocyte sex ratios in malarious
children in an endemic area. Parasitol Int 2009, 58:438–443.
30. Gbotosho GO, Sowunmi A, Happi CT, Okuboyejo TM: Plasmodium
falciparum gametocyte carriage, sex ratios and asexual parasite rates in
Nigerian children before and after a treatment protocol policy change
instituting the use of artemisinin-based combination therapies. Mem Inst
Oswaldo Cruz 2011, 106:685–690.
31. Gbotosho GO, Sowunmi A, Okuboyejo TM, Happi CT, Michael OS, Folarin
OA, Adewoye EO: Plasmodium falciparum gametocyte carriage, emergence,
clearance and population sex ratios in anaemic and non-anaemic malarious
children. Mem Inst Oswaldo Cruz 2011, 106:562–569.32. Delves MJ, Ruecker A, Straschil U, Lelièvre J, Marques S, López-Barragán MJ,
Herreros E, Sinden RE: Male and female Plasmodium falciparum mature
gametocytes show different responses to antimalarial drugs. Antimicrob
Agents Chemother 2013, 57:3268–3274.
33. Mollow W: Uber die gameten-zerstorende Wirkung des Plasmochins.
Arch Schiffs TropenHyg 1928, 32:116–119.
34. Shute PG, Maryon M: A study of gametocytes in a West African strain of
Plasmodium falciparum. Trans R Soc Trop Med Hyg 1951, 44:421–438.
35. White NJ: The parasite clearance curve. Malar J 2011, 10:278.
36. Bousema T, Okell L, Shekalaghe S, Griffin JT, Omar S, Sawa P, Sutherland C,
Sauerwein R, Ghani AC, Drakeley C: Revisiting the circulation time of
Plasmodium falciparum gametocytes: molecular detection methods to
estimate the duration of gametocyte carriage and the effect of
gametocytocidal drugs. Malar J 2010, 9:136.
37. Babiker HA, Schneider P, Reece SE: Gametocytes: insights gained during a
decade of molecular monitoring. Trends Parasitol 2008, 24:525–530.
38. Schneider P, Reece S, van Schaijk B, Meaden C, Ranford-Cartwright L, Gadalla
A, Babiker H: Quantification of male and female Plasmodium falciparum
gametocytes by real-time PCR. Mol Biol Parasitol 2014, in press.
39. Tao D, Ubaida-Mohien C, Mathias DK, King JG, Pastrana-Mena R, Tripathi A,
Goldowitz I, Graham DR, Moss E, Marti M, Dinglasan RR: Sex-partitioning of
the Plasmodium falciparum stage V gametocyte proteome provides
insight into falciparum-specific cell biology. Mol Cell Proteomics 2014,
13:2705–2724.
40. Barnes KI, Little F, Mabuza A, Mngomezulu N, Govere J, Durrheim D, Roper
C, Watkins B, White NJ: Increased gametocytemia after treatment: an
early parasitological indicator of emerging sulfadoxine- pyrimethamine
resistance in falciparum malaria. J Infect Dis 2008, 197:1605–1613.
41. Distiller GB, Little F, Barnes KI: Nonlinear mixed effects modeling of
gametocyte carriage in patients with uncomplicated malaria. Malar J
2010, 9:60.
42. Stepniewska K, Price RN, Sutherland CJ, Drakeley CJ, von Seidlein L, Nosten
F, White NJ: Plasmodium falciparum gametocyte dynamics in areas of
different malaria endemicity. Malar J 2008, 7:249.
43. Jeffery GM, Eyles DE: Infectivity to mosquitoes of Plasmodium falciparum
as related to gametocyte density and duration of infection. Am J Trop
Med Hyg 1955, 4:781–789.
44. Churcher TS, Bousema T, Walker M, Drakeley C, Schneider P, Ouédraogo AL,
Basáñez MG: Predicting mosquito infection from Plasmodium falciparum
gametocyte density and estimating the reservoir of infection. E-life 2013,
2:e00626.
45. Shute PG, Maryon M: Laboratory Technique for the Study of Malaria. 2nd
edition. London: J&A Churchill Ltd; 1966.
46. Bousema T, Dinglasan RR, Morlais I, Gouagna LC, van Warmerdam T, Awono-
Ambene PH, Bonnet S, Diallo M, Coulibaly M, Tchuinkam T, Mulder B, Targett G,
Drakeley C, Sutherland C, Robert V, Doumbo O, Touré Y, Graves PM, Roeffen W,
Sauerwein R, Birkett A, Locke E, Morin M, Wu Y, Churcher TS:Mosquito feeding
assays to determine the infectiousness of naturally infected Plasmodium
falciparum gametocyte carriers. PLoS One 2012, 7:e42821.
47. Churcher TS, Blagborough AM, Delves M, Ramakrishnan C, Kapulu MC,
Williams AR, Biswas S, Da DF, Cohuet A, Sinden RE: Measuring the
blockade of malaria transmission - an analysis of the standard
membrane feeding assay. Int J Parasitol 2012, 42:1037–1044.
48. Kone A, van de Vegte-Bolmer M, Siebelink-Stoter R, van Gemert GJ, Dara A,
Niangaly H, Luty A, Doumbo OK, Sauerwein R, Djimde AA: Sulfadoxine-
pyrimethamine impairs Plasmodium falciparum gametocyte infectivity
and Anopheles mosquito survival. Int J Parasitol 2010, 40:1221–1228.
49. Beavogui AH, Djimde AA, Gregson A, Toure AM, Dao A, Coulibaly B,
Ouologuem D, Fofana B, Sacko A, Tekete M, Kone A, Niare O, Wele M,
Plowe CV, Picot S, Doumbo OK: Low infectivity of Plasmodium falciparum
gametocytes to Anopheles gambiae following treatment with
sulfadoxine-pyrimethamine in Mali. Int J Parasitol 2010, 40:1213–1220.
50. Ouedraogo AL, Bousema T, Schneider P, de Vlas SJ, Ilboudo-Sanogo E,
Cuzin-Ouattara N, Nébié I, Roeffen W, Verhave JP, Luty AJ, Sauerwein R:
Substantial contribution of submicroscopical Plasmodium falciparum
gametocyte carriage to the infectious reservoir in an area of seasonal
transmission. PLoS One 2009, 4:e8410.
51. Rosenberg R: Malaria: some considerations regarding parasite
productivity. Trends Parasitol 2008, 24:487–491.
52. Rieckmann KH, McNamara JV, Frischer H, Stockert TA, Carson PE, Powell RD:
Gametocytocidal and sporontocidal effects of primaquine and of
White et al. Malaria Journal 2014, 13:483 Page 13 of 13
http://www.malariajournal.com/content/13/1/483sulfadiazine with pyrimethamine in a chloroquine-resistant strain of
Plasmodium falciparum. Bull World Health Organ 1968, 38:625–632.
53. Young MD: The effect of small doses of primaquine upon malaria
infections. Indian J Malariol 1959, 13:69–74.
54. Roehl W: Malariatherapie mit Plasmochin in Spanien. Arch Schiffs
TropenHyg 1927, 31:48–58.
55. Barber MA, Komp WHW: The Viability of Gametocytes in the Blood of
Plasmochin-Treated Patients, 16th Ann Rept Med Dept United Fruit Co.;
1927:60–62.
56. Barber MA, Komp WH, Newman BM: The effect of small doses of
plasmochin on the viability of gametocytes of malaria as measured by
mosquito infection experiments. Public Health Rep 1929, 44:1409–1420.
57. Jerace F, Giovannola A: L’azzione sterlizzante della plasmochina sui
gametociti di parassiti malarigenie sua importanza profilattica. Riv
Malariol 1933, 12:457–477.
58. Manson-Bahr PH: Further observations on the effects of plasmochin and
“plasmochin-compound” on the gametocytes of benign tertian and
subtertian malaria. Lancet 1928, 214:25–26.
59. MacKerras MJ, Ercole QN: Observations on the action of quinine, atebrin
and plasmoquine on the gametocytes of Plasmodium falciparum.
Trans R Soc Trop Med Hyg 1949, 42:455–463.
60. Edgecomb JH, Arnold J, Yount EH Jr, Alving AS, Eichelberger L, Jeffery GM,
Eyles D, Young MD: Primaquine, SN 13272, a new curative agent in vivax
malaria; a preliminary report. J Natl Malar Soc 1950, 9:285–292.
61. Rieckmann KH, McNamara JV, Kass L, Powell RD: Gametocytocidal and
sporontocidal effects of primaquine upon two strains of Plasmodium
falciparum. Mil Med 1969, 134:802–819.
62. Delves MJ, Ramakrishnan C, Blagborough AM, Leroy D, Wells TNC, Sinden
RE: A high throughput assay for the identification of malarial
transmission-blocking drugs and vaccines. Int J Parasitol 2012,
42:999–1006.
63. Ruecker A, Mathias DK, Straschil U, Churcher TS, Dinglasan RR, Leroy D,
Sinden RE, Delves MJ: A male and female gametocyte functional viability
assay to identify biologically relevant malaria transmission-blocking
drugs. Antimicrob Agents Chemother 2014, 58:7292–7302.
64. Pybus BS, Marcsisin SR, Jin X, Deye G, Sousa JC, Li Q, Caridha D, Zeng Q,
Reichard GA, Ockenhouse C, Bennett J, Walker LA, Ohrt C, Melendez V: The
metabolism of primaquine to its active metabolite is dependent on CYP
2D6. Malar J 2013, 12:212.
doi:10.1186/1475-2875-13-483
Cite this article as: White et al.: Assessment of therapeutic responses to
gametocytocidal drugs in Plasmodium falciparum malaria. Malaria
Journal 2014 13:483.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
